Table 1 Baseline Patients Characteristics
Study cohort (n = 46) | |
|---|---|
Age, years | |
Median | 63.1 |
Range | 41.1–84.0 |
Sex - No. (%) | |
Male | 29 (63.0) |
Female | 17 (37.0) |
WHO performance status - No. (%) | |
0 | 30 (65.2) |
1 | 16 (34.8) |
2 | 0 (0.0) |
Site of metastases - No. (%) | |
Brain | 1 (2.2) |
Lung | 35 (76.1) |
Pleura | 3 (6.5) |
Liver | 4 (8.7) |
Bone | 16 (34.8) |
Lymph nodes | 28 (60.9) |
Number of disease sites - No. (%) | |
1 | 10 (21.7) |
2 | 11 (23.9) |
≥ 3 | 25 (54.3) |
Hypertension before treatment - No. (%) | |
Yes | 24 (52.2) |
No | 22 (47.8) |
IMDC risk score – No. (%) | |
Good | 7 (15.2) |
Intermediate | 16 (34.8) |
Poor | 21 (45.7) |
Missing | 2 (4.3) |
Time from initial diagnosis - No. (%) | |
≤ 12 months | 33 (71.7) |
> 12 months | 13 (28.3) |
Prior removal of primary tumor - No. (%) | |
Radical nephrectomy | 24 (52.2) |
Partial nephrectomy | 2 (4.3) |
No | 20 (43.5) |